"Dr. Cruz Quips......Live From New York City"
OK Not so live but as live as it gets.....LOL! And by the way ..... in no particular order.
Dr. Cruz......"E1-INT showed a decrease of 0.94-1.21% in HB1C Levels. Byetta got accepted with 0.92% and DPP-IV Inhibitors at around 0.65%. So this is quite competitive compared to currently marketed products!"
Dr. Cruz......."Treat one month (E1-INT) get 6 months of sustained effects, which has NEVER been shown before."
.......Recall Transitions DPP-IV Inhibitor+G1 Program is currently going through Pre-Clinicals at lightning speed!!
Merck has a recently approved (04/07) DPP-IV Inhibitor.
Byetta (proprietary GLP1 Analogue+Metformin/TZD) a twice daily injection is pulling in BlockBuster Sales........in its second year......
Looks good for the Gastrin Based Therapies future considering E1-INT had effects of decreased HB1C levels for 6 MONTHS post treatment.........thats 24 weeks before having to even think about re-treatment.